Institution
ACADIA Pharmaceuticals Inc.
Company•San Diego, California, United States•
About: ACADIA Pharmaceuticals Inc. is a company organization based out in San Diego, California, United States. It is known for research contribution in the topics: Pimavanserin & Receptor. The organization has 260 authors who have published 276 publications receiving 8418 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Practical conditions for the synthesis of 4-substituted N-protected piperidines through CuCN·2LiBr-catalyzed organozinc additions to 1-acylpyridinium salts and subsequent hydrogen-transfer hydrogen transfer are given in this paper.
27 citations
••
TL;DR: A class of small molecules displaying comparable activities with peptide ligands BAM22 and corticostatin-14 at both the human and rhesus monkey MrgX1 andMrgX2 receptors, respectively, was discovered.
27 citations
••
01 Jan 2018TL;DR: Pimavanserin demonstrated significant efficacy in AD psychosis in patients with higher baseline severity of psychotic symptoms (NPI-NH-PS ≥12), and treatment with pimavANSerin showed an acceptable tolerability profile.
Abstract: Pimavanserin is a 5-HT2A receptor inverse agonist/antagonist and is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis Evaluate the efficacy of pimavanserin on symptoms of psychosis in patients with Alzheimer’s disease (AD) Randomized, double-blind, placebo-controlled trial Nursing home residents Patients with AD psychosis Pimavanserin 34 mg or placebo daily for 12 weeks The primary endpoint was mean change from baseline at Week 6 on the Neuropsychiatric Inventory-Nursing Home Version psychosis score (NPI-NH-PS) In the prespecified subgroup analysis, the mean change in NPI-NH-PS and the responder rates among those with baseline NPI-NH-PS ≥12 were evaluated Of 181 patients randomized (n=90 pimavanserin; n=91 placebo), 57 had baseline NPI-NH-PS ≥12 (n=27 pimavanserin; n=30 placebo) In this severe subgroup, large treatment effects were observed (delta=-443, Cohen’s d=-073, p=0011), and ≥30% improvement was 889% vs 433% (p<0001) and ≥50% improvement was 778% vs 433% (p=0008) for pimavanserin and placebo, respectively The rate of adverse events (AEs) in the severe subgroup was similar between treatment groups, and urinary tract infection, fall, and agitation were most frequent Serious AEs was similar with pimavanserin (179%) and placebo (167%) with fewer discontinuations due to AEs with pimavanserin (71%) compared to placebo (100%) Minimal change from baseline occurred for the mean MMSE score over 12 weeks Pimavanserin demonstrated significant efficacy in AD psychosis in patients with higher baseline severity of psychotic symptoms (NPI-NH-PS ≥12) Treatment with pimavanserin showed an acceptable tolerability profile
27 citations
••
TL;DR: The synthesis of alpha-substituted alpha,beta-enones by a new metal iodide-promoted one-pot three-component reaction involving commercially available cyclopropyl ketones, aldehydes, and secondary amines followed by base treatment is described.
27 citations
•
23 Dec 2002TL;DR: In this article, the tetrahydroquinoline compounds as muscarinic receptor agonists, compositions comprising the same, methods of inhibiting an activity of a muscarinic receptor with said compounds, and methods for identifying a subject suitable for treatment using said compounds.
Abstract: The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
26 citations
Authors
Showing all 261 results
Name | H-index | Papers | Citations |
---|---|---|---|
Michael Bachmann | 63 | 360 | 14388 |
Daniel P. van Kammen | 47 | 168 | 6957 |
Kristina Luthman | 39 | 158 | 7344 |
Fredrik Almqvist | 37 | 170 | 4219 |
Mark R. Brann | 35 | 77 | 5579 |
Roger Olsson | 30 | 138 | 2752 |
Uli Hacksell | 29 | 99 | 2954 |
Torbjörn Frejd | 29 | 165 | 2889 |
Petrine Wellendorph | 27 | 83 | 2573 |
Ethan S. Burstein | 27 | 70 | 2255 |
David M. Weiner | 26 | 45 | 3230 |
Kimberly E. Vanover | 25 | 70 | 1955 |
Uli Hacksell | 25 | 129 | 2879 |
Magnus Gustafsson | 25 | 94 | 1546 |
Mark R. Brann | 24 | 39 | 2576 |